<DOC>
	<DOCNO>NCT02864095</DOCNO>
	<brief_summary>The purpose study compare blood loss intravenous topical administration low dose epinephrine plus combined administration intravenous topical tranexamic acid primary total hip arthroplasty .</brief_summary>
	<brief_title>Intravenous Versus Topical Administration Low Dose Epinephrine Plus Combined Administration Intravenous Topical Tranexamic Acid ( TXA ) Primary Total Hip Arthroplasty</brief_title>
	<detailed_description />
	<mesh_term>Epinephrine</mesh_term>
	<mesh_term>Racepinephrine</mesh_term>
	<mesh_term>Epinephryl borate</mesh_term>
	<mesh_term>Tranexamic Acid</mesh_term>
	<criteria>All patient age 20 75 diagnosed osteoarthritis osteonecrosis femoral head Scheduled elective primary total hip arthroplasty Those willing able return followup least 6month postoperative period Acute coronary syndrome &lt; 6 month Glaucoma , pheochromocytoma , thyrotoxicosis , digoxin intoxication , serum potassium &lt; 3.0 mmol , alcohol abuse , premenopausal woman Current treatment adenosine diphosphate ( ADP ) receptor antagonist , Factor Xa thrombin inhibitor , heparin ( exclude Low Molecular Weight Heparin ( LMWH ) perioperative thromboprophylaxis ) , tricyclic antidepressant , monoamine oxidaseï¼ˆMAO ) CatecholOmethyltransferase ( COMT ) inhibitor Patients history thromboembolic disease , bleed disorder Patients history renal impairment , cardiovascular disease ( previous myocardial infarction , atrial fibrillation ) cerebrovascular condition ( previous stroke peripheral vascular surgery ) Allergy TXA</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Arthroplasty , Replacement , Hip</keyword>
	<keyword>Epinephrine</keyword>
	<keyword>Tranexamic acid</keyword>
</DOC>